Emmerich K, Klos M, Ulbricht L J, Krakau I, Probst H
Medizinische Klinik B, Herzzentrum Wuppertal, Klinikum Wuppertal der Universität Witten/Herdecke.
Dtsch Med Wochenschr. 1997 Oct 2;122(40):1201-6. doi: 10.1055/s-2008-1047748.
The time elapsed until effective infarct vessel perfusion has been identified as an essential determinant of survival after acute myocardial infarction (MI). Significant mortality rate reduction has not been demonstrated for patients who received thrombolytic treatment more than 12 to 24 hours after MI. For this reason such patients have so far largely been denied reperfusion treatment and have thus been excluded from any potential benefit of an reopened infarct vessel. It was the aim of this study to assess the applicability and safety of achieving reperfusion by percutaneous transluminal coronary angioplasty (PTCA) without prior thrombolysis (primary PTCA) within 12 (> 12) to 24 (< or = 24) hours after onset of pain, taking into account early and late results in selected consecutive patients.
The data were analysed retrospectively of 35 patients (29 men, 6 women; mean age 60 [49-78] years) who had been admitted and treated by primary PTCA for MI more than 12-24 hours after onset of pain, with persisting ECG changes and (or) continuing chest pain. Reperfusion rates, acute haemodynamic parameters, acute cardiac and noncardiac complications, 30-day mortality rate, 3-month angiographic results and late mortality rate were obtained after an average of 23 (4-36) months.
Complete infarct vessel reperfusion was achieved in 30 patients (85.7%), the infarct vessel remaining occluded in five. The early measurement of mean left ventricular ejection fraction was 53% (8-76%). A small, conservatively managed pericardial effusion occurred in one patient due to coronary artery penetration. Three patients who were in cardiogenic shock on admission died (8.6% 30-day mortality rate). Nine cases of restenosis and two of re-occlusion of the infarct vessel were documented in 24 patients who were investigated invasively 3 months after the primary PTCA. One patient had sustained a nonfatal MI. During the follow-up period one patient died of a noncardiac cause.
In this selected group of patients who received treatment more than 12 to 24 hours after MI primary PTCA achieved a high rate of reperfusion, while early and late complications were rare. Using individualized criteria of patient selection, primary PTCA can accomplish recanalization. The question of prognostic advantage can only be answered by results in a larger and randomized cohort of patients.
急性心肌梗死(MI)后,直至梗死血管实现有效灌注所经历的时间已被确认为生存的关键决定因素。对于心肌梗死后12至24小时以上接受溶栓治疗的患者,尚未证实其死亡率有显著降低。因此,这类患者迄今为止在很大程度上被剥夺了再灌注治疗,从而被排除在梗死血管再通的任何潜在益处之外。本研究的目的是评估在疼痛发作后12(>12)至24(≤24)小时内,不进行预先溶栓(直接经皮冠状动脉腔内血管成形术,primary PTCA)实现再灌注的适用性和安全性,并考虑选定连续患者的早期和晚期结果。
回顾性分析35例患者(29例男性,6例女性;平均年龄60[49 - 78]岁)的数据,这些患者在疼痛发作后12 - 24小时以上因心肌梗死入院并接受直接经皮冠状动脉腔内血管成形术治疗,伴有持续的心电图改变和(或)持续胸痛。在平均23(4 - 36)个月后,获得再灌注率、急性血流动力学参数、急性心脏和非心脏并发症、30天死亡率、3个月血管造影结果及晚期死亡率。
30例患者(85.7%)实现了梗死血管完全再灌注,5例梗死血管仍闭塞。早期平均左心室射血分数测量值为53%(8 - 76%)。1例患者因冠状动脉穿孔出现少量、经保守治疗的心包积液。3例入院时处于心源性休克的患者死亡(30天死亡率8.6%)。在直接经皮冠状动脉腔内血管成形术3个月后接受有创检查的24例患者中,记录到9例再狭窄和2例梗死血管再闭塞。1例患者发生非致命性心肌梗死。在随访期间,1例患者死于非心脏原因。
在这组选定的心肌梗死后12至24小时以上接受治疗的患者中,直接经皮冠状动脉腔内血管成形术实现了较高的再灌注率,而早期和晚期并发症罕见。采用个体化的患者选择标准,直接经皮冠状动脉腔内血管成形术可实现血管再通。预后优势问题只能通过更大规模随机分组患者的研究结果来回答。